These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 25686137)

  • 21. A randomised Phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis.
    Jindani A; Borgulya G; de Patiño IW; Gonzales T; de Fernandes RA; Shrestha B; Atwine D; Bonnet M; Burgos M; Dubash F; Patel N; Checkley AM; Harrison TS; Mitchison D;
    Int J Tuberc Lung Dis; 2016 Jun; 20(6):832-8. PubMed ID: 27155189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Six-months chemotherapy (2HRZS or E/4HRE) of new cases of pulmonary tuberculosis--six year experiences on its effectiveness, toxicity, and acceptability].
    Wada M; Yoshiyama T; Ogata H; Ito K; Mizutani S; Sugita H
    Kekkaku; 1999 Apr; 74(4):353-60. PubMed ID: 10355221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical response of newly diagnosed HIV seropositive & seronegative pulmonary tuberculosis patients with the RNTCP Short Course regimen in Pune, India.
    Tripathy S; Anand A; Inamdar V; Manoj MM; Khillare KM; Datye AS; Iyer R; Kanoj DM; Thakar M; Kale V; Pereira M; Risbud AR
    Indian J Med Res; 2011 May; 133(5):521-8. PubMed ID: 21623038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.
    Thee S; Seddon JA; Donald PR; Seifart HI; Werely CJ; Hesseling AC; Rosenkranz B; Roll S; Magdorf K; Schaaf HS
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5560-7. PubMed ID: 21968358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Short-course chemotherapy of tuberculosis with pyrazinamide].
    Asai S; Futsuki Y; Tomari S; Araki J
    Nihon Rinsho; 1998 Dec; 56(12):3087-90. PubMed ID: 9883615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Electronic pillbox-enabled self-administered therapy versus standard directly observed therapy for tuberculosis medication adherence and treatment outcomes in Ethiopia (SELFTB): protocol for a multicenter randomized controlled trial.
    Manyazewal T; Woldeamanuel Y; Holland DP; Fekadu A; Blumberg HM; Marconi VC
    Trials; 2020 May; 21(1):383. PubMed ID: 32370774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequency of recurrence among MDR-tB cases 'successfully' treated with standardised short-course chemotherapy.
    Migliori GB; Espinal M; Danilova ID; Punga VV; Grzemska M; Raviglione MC
    Int J Tuberc Lung Dis; 2002 Oct; 6(10):858-64. PubMed ID: 12365571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment outcome of new culture positive pulmonary tuberculosis in Norway.
    Farah MG; Tverdal A; Steen TW; Heldal E; Brantsaeter AB; Bjune G
    BMC Public Health; 2005 Feb; 5():14. PubMed ID: 15698472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up.
    Su WJ; Perng RP
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):1029-32. PubMed ID: 12475151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009.
    Gegia M; Cohen T; Kalandadze I; Vashakidze L; Furin J
    Int J Tuberc Lung Dis; 2012 Jun; 16(6):812-6. PubMed ID: 22507372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status.
    Ramachandran G; Kumar AK; Kannan T; Bhavani PK; Kumar SR; Gangadevi NP; Banurekha VV; Sudha V; Venkatesh S; Ravichandran N; Kalpana S; Mathevan G; Sanjeeva GN; Agarwal D; Swaminathan S
    Pediatr Infect Dis J; 2016 May; 35(5):530-4. PubMed ID: 26825153
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prescriptions and dosages of anti-tuberculosis drugs in the National Tuberculosis Control Programme of Malawi.
    Harries AD; Gausi F; Salaniponi FM
    Int J Tuberc Lung Dis; 2004 Jun; 8(6):724-9. PubMed ID: 15182142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of the 6-month thrice-weekly regimen in the treatment of new sputum smear-positive pulmonary tuberculosis under clinical trial conditions.
    Banu Rekha VV; Rajaram K; Kripasankar AS; Parthasarathy R; Umapathy KC; Sheikh I; Selvakumar N; Victor M; Niruparani C; Sridhar R; Jawahar MS
    Natl Med J India; 2012; 25(4):196-200. PubMed ID: 23278775
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Tuberculosis Research Centre.
    Int J Tuberc Lung Dis; 1997 Dec; 1(6):509-17. PubMed ID: 9487448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Six-month short course chemotherapy containing pyrazinamide for initial treatment of pulmonary tuberculosis].
    Wada M; Yosiyama T; Yosikawa M; Ogata H; Sugie T; Nakasono T; Sugita H
    Kekkaku; 1994 Nov; 69(11):671-80. PubMed ID: 7837720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Side-effects of drugs used in directly observed treatment short-course in newly diagnosed pulmonary tuberculosis subjects in Nigerians: a controlled clinical study.
    Dosumu EA
    Niger Postgrad Med J; 2002 Mar; 9(1):34-7. PubMed ID: 11932759
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus.
    Kumar AK; Chandrasekaran V; Kannan T; Murali AL; Lavanya J; Sudha V; Swaminathan S; Ramachandran G
    Eur J Clin Pharmacol; 2017 Jan; 73(1):65-70. PubMed ID: 27651240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.
    Swaminathan S; Narendran G; Venkatesan P; Iliayas S; Santhanakrishnan R; Menon PA; Padmapriyadarsini C; Ramachandran R; Chinnaiyan P; Suhadev M; Sakthivel R; Narayanan PR
    Am J Respir Crit Care Med; 2010 Apr; 181(7):743-51. PubMed ID: 19965813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of a non-rifampicin continuation phase (6HE) following thrice-weekly intensive phase for the treatment of new sputum positive pulmonary tuberculosis.
    Indian J Tuberc; 2007 Apr; 54(2):84-90. PubMed ID: 17575680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.